Compare BURL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BURL | GMAB |
|---|---|---|
| Founded | 1972 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 17.4B |
| IPO Year | 2013 | N/A |
| Metric | BURL | GMAB |
|---|---|---|
| Price | $250.68 | $31.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $336.57 | $40.40 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.59 | ★ 132.41 |
| EPS | 8.72 | ★ 25.10 |
| Revenue | ★ $11,187,977,000.00 | $3,845,670,022.00 |
| Revenue This Year | $9.78 | $24.92 |
| Revenue Next Year | $9.68 | $15.97 |
| P/E Ratio | $28.55 | ★ $1.26 |
| Revenue Growth | 6.81 | ★ 29.57 |
| 52 Week Low | $212.92 | $17.24 |
| 52 Week High | $309.00 | $33.65 |
| Indicator | BURL | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 60.90 |
| Support Level | $240.49 | $31.32 |
| Resistance Level | $265.46 | $32.48 |
| Average True Range (ATR) | 10.29 | 0.61 |
| MACD | -4.27 | 0.15 |
| Stochastic Oscillator | 16.11 | 72.06 |
Burlington Stores Inc is off-price retailer offering an extensive selection of in-season, fashion-focused merchandise including: women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts and coats. Company sell a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. Company sell product in category such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby and Outerwear.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.